Nesiritide

Mechanism

A synthetic version of BNP (B-type Natriuretic Peptide), the hormone your heart releases when it's overstretched. It relaxes blood vessels, reduces fluid overload, and takes pressure off the heart. FDA-approved for acute heart failure (IV only). Your doctor may test your blood BNP levels to check for heart failure — this is the therapeutic version.

Effects

## Detailed Effects — Nesiritide ### Cardiovascular System — Hemodynamics [Tier 1] - Recombinant human B-type natriuretic peptide (BNP, 32 amino acids). Identical to endogenous BNP released by ventricular cardiomyocytes in response to volume overload and wall stress. - Binds natriuretic peptide receptor A (NPR-A) → increases intracellular cGMP → vasodilation (venous > arterial), natriuresis, diuresis, and neurohormonal modulation. - Hemodynamic effects: reduces pulmonary capillary wedge pressure (PCWP) by 5-8 mmHg within 15 minutes, reduces systemic vascular resistance, and modestly increases cardiac output. - **VMAC Trial (JAMA 2002, n=489)**: Nesiritide reduced PCWP significantly more than nitroglycerin at 3 hours. Improved dyspnea at 3 hours. - **ASCEND-HF Trial (O'Connor et al., NEJM 2011, n=7,141)**: Definitive trial. Nesiritide did NOT reduce 30-day death or HF rehospitalization. Small improvement in dyspnea that was not clinically significant. However, it did NOT worsen renal function or increase mortality — resolving prior safety concerns. ### Renal System [Tier 1] - Promotes natriuresis and diuresis by increasing renal cGMP, dilating afferent arterioles, and inhibiting sodium reabsorption in the collecting duct. - Sackner-Bernstein meta-analysis (2005) raised concerns about worsened renal function — this was REFUTED by ASCEND-HF which showed no renal harm. - Does not replace diuretics. Used adjunctively when IV diuretics alone are insufficient. ### Neurohormonal [Tier 1-2] - Suppresses renin-angiotensin-aldosterone system (RAAS) activation — reduces plasma aldosterone levels. - Reduces sympathetic nervous system activation. - These neurohormonal effects are theoretically beneficial in heart failure but did not translate to mortality benefit in ASCEND-HF.

Practitioner Guide

## Practitioner Guide — Nesiritide ### Current Clinical Role - **Largely fallen out of favor** following ASCEND-HF. Still FDA-approved (Natrecor) for acute decompensated heart failure (ADHF) but rarely used. - Primary indication: ADHF with dyspnea at rest — as an adjunct to IV diuretics when diuretics alone are insufficient. - HOSPITAL USE ONLY. Requires hemodynamic monitoring. ### Dosing Protocol - **Loading dose**: 2 mcg/kg IV bolus over 60 seconds. - **Maintenance**: 0.01 mcg/kg/min continuous IV infusion. - **Duration**: Up to 48 hours. Can extend if clinically needed but data beyond 48h is limited. - **Dose titration**: If hypotension occurs, reduce or stop infusion. If inadequate response, can increase to 0.015 mcg/kg/min (max 0.03 mcg/kg/min). - **Do NOT bolus in patients with systolic BP <90 mmHg**. ### Reconstitution & Administration - Natrecor vial: 1.5 mg lyophilized powder. - Reconstitute with supplied diluent (5% dextrose). Then dilute in 250 mL D5W or NS bag for IV infusion. - Final concentration: 6 mcg/mL when diluted in 250 mL. - Use dedicated IV line or flush line with D5W before and after. - Incompatible with heparin, bumetanide, enalaprilat, hydralazine — do not co-administer through same IV line. ### Monitoring - Continuous telemetry and blood pressure monitoring. Hold infusion if SBP drops below 90 mmHg. - Urine output monitoring (hourly). - Basic metabolic panel (BMP) daily — creatinine, electrolytes. - BNP levels are NOT useful for monitoring while on nesiritide (exogenous BNP will elevate the lab value). ### Why It Fell Out of Favor - ASCEND-HF showed no mortality benefit and no meaningful clinical benefit beyond modest dyspnea improvement. - Cost: ~$1,000-3,000 per treatment course vs pennies for IV nitroglycerin or furosemide. - Requires central monitoring and ICU-level care. - Most heart failure specialists now use IV diuretic optimization, nitroglycerin drips, or milrinone/dobutamine instead. ### Storage - Lyophilized vial: store at room temperature (20-25°C). Do not freeze. - Reconstituted solution: use within 24 hours. Refrigerate if not used immediately.

Dosing Protocols

Contraindications & Cautions

• hard stop — Hypotension (SBP < 90 mmHg)
  Nesiritide (Natrecor) causes significant blood pressure reduction via vasodilation and natriuresis. In patients with baseline hypotension, it can precipitate cardiogenic shock, end-organ failure, and death.
  Action: Do not use in patients with systolic BP < 90 mmHg. This is a labeled contraindication.
• hard stop — Cardiogenic shock
  Nesiritide should not be used as primary therapy for cardiogenic shock. Vasodilation in the setting of pump failure can cause cardiovascular collapse.
  Action: Do not use in cardiogenic shock. Inotropes and mechanical support are appropriate first-line treatments.
• hard stop — Pregnancy
  No adequate human data. Significant hemodynamic effects during pregnancy could compromise uteroplacental blood flow.
  Action: Do not use during pregnancy.
• hard stop — Under 18 years of age
  Not for pediatric use outside specialist cardiac care.
  Action: Do not provide to individuals under 18.
• caution — Renal impairment
  Nesiritide may worsen renal function. Post-marketing data and meta-analyses have raised concerns about increased risk of worsening renal failure and dialysis in some patient populations.
  Action: Monitor renal function closely (creatinine, BUN, urine output). Discontinue if renal function deteriorates.

Evidence

• Comparative efficacy of different drugs in acute heart failure with renal dysfunction: a systematic review and network meta-analysis.

  Lv et al. (2024) — Frontiers in Cardiovascular Medicine — PMID: 39877019

  Network meta-analysis of 13 studies (21,745 patients) in acute heart failure with renal dysfunction found no mortality advantage for nesiritide and reported better NT-proBNP reduction with high-dose diuretics and better GFR improvement with levosimendan, supporting a more limited role for nesiritide in this setting.

  moderate

• Effect of Nesiritide in Patients with Acute Decompensated Heart Failure (ASCEND-HF)

  O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalan R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Mendez GF, Metra M, Mitber S, Moe GW, Rogers JG, Adler ED, Piña IL, Ponikowski P, Ristic AD, Rocio AR, Rosenberg Y, Saldarriaga C, Seltzer JH, Simmons EE, Skopicki HA, Stough WG, Swedberg K, Udell JA, Velazquez EJ, Voors AA, Wiber CE, Zannad F, Califf RM (2011) — New England Journal of Medicine — PMID: 21631327

  ASCEND-HF trial (n=7141) showed nesiritide did not reduce 30-day death or HF rehospitalization vs placebo in acute decompensated HF. A small improvement in dyspnea was seen but was not clinically significant. Importantly, nesiritide did NOT increase mortality or worsen renal function, resolving prior safety concerns. Results led to decreased clinical use, as the modest benefit did not justify the cost and complexity of IV administration.

  strong

• Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial (VMAC)

  Publication Committee for the VMAC Investigators (2002) — JAMA — PMID: 11886298

  Nesiritide (recombinant BNP) reduced pulmonary capillary wedge pressure more effectively than nitroglycerin and significantly improved dyspnea in acute decompensated heart failure (VMAC trial). Mechanism involves natriuretic peptide receptor activation causing vasodilation, natriuresis, and neurohormonal modulation. FDA-approved in 2001 for acute HF but use declined after safety concerns were raised.

  moderate

Research Summary

## Research Summary — Nesiritide ### Tier 1: Randomized Controlled Trials - **VMAC Trial (JAMA 2002, n=489)**: Nesiritide superior to nitroglycerin for PCWP reduction and early dyspnea relief in ADHF. Led to FDA approval and initial enthusiasm. - **ASCEND-HF (O'Connor et al., NEJM 2011, n=7,141)**: Definitive large RCT. Nesiritide did NOT reduce 30-day death or HF rehospitalization vs placebo. Small, not clinically significant dyspnea improvement. Did NOT worsen renal function or increase mortality. Effectively ended widespread clinical use. - **ROSE Trial (Chen et al., JAMA 2013, n=360)**: Low-dose nesiritide (0.005 mcg/kg/min without bolus) did not enhance decongestion when added to IV diuretics in ADHF. Another negative trial. ### Tier 2: Systematic Reviews & Meta-Analyses - **Sackner-Bernstein et al., Circulation 2005**: Meta-analysis raised concern about increased risk of worsening renal function with nesiritide. This triggered the ASCEND-HF trial, which ultimately refuted the renal harm signal. - Post-ASCEND-HF reviews: consensus that nesiritide is safe but not effective enough to justify routine use. - Cost-effectiveness analyses uniformly unfavorable given lack of hard clinical endpoints. ### Tier 3: Case Reports & Practitioner Protocols - Some cardiologists still use nesiritide in select cases: patients who cannot tolerate nitroglycerin, severely volume-overloaded patients not responding to diuretics. - Anecdotal reports of outpatient nesiritide infusions at advanced heart failure clinics — not evidence-based. ### Gaps - Whether specific heart failure subgroups (e.g., low BNP producers, preserved ejection fraction) might benefit is unexplored. - No trials in combination with newer HF therapies (SGLT2 inhibitors, sacubitril-valsartan). ### Active Trials - Minimal ongoing trial activity for nesiritide. The heart failure field has moved on to sacubitril-valsartan, SGLT2 inhibitors, and other novel agents.